These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7843638)

  • 1. Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease.
    Lusher JM
    Haemostasis; 1994; 24(5):276-84. PubMed ID: 7843638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
    Mohri H; Hashimoto Y; Yamazaki E; Kanamori H; Okubo T
    Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP).
    Mannucci PM; Bettega D; Cattaneo M
    Br J Haematol; 1992 Sep; 82(1):87-93. PubMed ID: 1419807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
    Santiago-Borrero PJ; Casanova R
    Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
    Mannucci PM
    Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
    Warrier AI; Lusher JM
    J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease.
    Ragni MV; Jankowitz RC; Chapman HL; Merricks EP; Kloos MT; Dillow AM; Nichols TC
    Haemophilia; 2008 Sep; 14(5):968-77. PubMed ID: 18680527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
    Federici AB
    Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mild forms of von Willebrand disease: diagnosis and management.
    Federici AB
    Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches to management of bleeding disorders.
    Aledort LM
    Hosp Pract (Off Ed); 1989 Feb; 24(2):207-11, 214, 219-21 passim. PubMed ID: 2493009
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment and validation of a defined fluid restriction protocol in the use of subcutaneous desmopressin for children with inherited bleeding disorders.
    Mason JA; Robertson JD; McCosker J; Williams BA; Brown SA
    Haemophilia; 2016 Sep; 22(5):700-5. PubMed ID: 27385253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal fractionated administration of desamino-D-arginine vasopressin (DDAVP) in patients with von Willebrand's disease.
    Garicochea B; D'Amico EA; Bydlowski SP; Chamone DA
    Ann Hematol; 1991; 62(2-3):81-2. PubMed ID: 1903313
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease.
    Rodeghiero F; Castaman G; Mannucci PM
    Blood Rev; 1991 Sep; 5(3):155-61. PubMed ID: 1777748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of von Willebrand disease in Spain.
    Batlle J; Perez-Rodriguez A; Pinto JC; Fraga EL; Rodriguez-Trillo Tch A; Fernanda Lopez-Fernandez M
    Semin Thromb Hemost; 2011 Jul; 37(5):503-10. PubMed ID: 22102193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of DDAVP and cryoprecipitate in mild to moderate haemophilia A and von Willebrand's disease.
    Berry EW
    Prog Clin Biol Res; 1990; 324():269-78. PubMed ID: 2106689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder.
    Favaloro EJ
    Semin Thromb Hemost; 2011 Jul; 37(5):440-55. PubMed ID: 22102186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.